Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion Cancer Gene Ther
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion CANCER GENE THER
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study HEMATOL ONCOL
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma Haematologica
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary Future Oncol
International consensus on the initial diagnostic workup of cancer of unknown primary CRIT REV ONCOL HEMAT
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy TRANSPL CELL THER